The European Medicines Agency (EMA) has announced that its human medicines committee (CHMP) will begin a rolling review of data on mRNA-1273, a coronavirus (COVID-19) vaccine which is being developed by Moderna Biotech Spain. CHMP has already started reviewing the first batch of data, which is non-clinical, and will in due course review the data from large-scale clinical trials. The rolling review will continue until sufficient evidence is available to support a formal marketing authorisation application.